{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:21:21Z","timestamp":1793308881336,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000028","name":"Institute of Circulatory and Respiratory Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["NFRFE-2021-00713"],"award-info":[{"award-number":["NFRFE-2021-00713"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2025.102025","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:49:04Z","timestamp":1768031344000},"page":"102025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["DNA-based vaccines: Advances, applications, and future prospects"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-9491","authenticated-orcid":false,"given":"Zhichang Peter","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-8263","authenticated-orcid":false,"given":"Ziyan Rachel","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-7517","authenticated-orcid":false,"given":"Ranmal Avinash","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-8654","authenticated-orcid":false,"given":"Rongqi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0522-6733","authenticated-orcid":false,"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib1","first-page":"1629","article-title":"DNA-based vaccines: new possibilities for disease prevention and treatment","volume":"152","author":"Robinson","year":"1995","journal-title":"CMAJ"},{"key":"10.1016\/j.gendis.2025.102025_bib2","first-page":"368","article-title":"DNA-based Immunization","volume":"5","author":"Davis","year":"1995","journal-title":"Mol Cell Biol Hum Dis Ser"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/fmb.15.110","article-title":"DNA-based influenza vaccines as immunoprophylactic agents toward universality","volume":"11","author":"Zhang","year":"2016","journal-title":"Future Microbiol"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib4","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1097\/JS9.0000000000002117","article-title":"Recent advances in HPV biotechnology: understanding host-virus interactions and cancer progression\u2013a review","volume":"110","author":"Yousaf","year":"2024","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.gendis.2025.102025_bib6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.gendis.2025.102025_bib7","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.gendis.2025.102025_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10332","key":"10.1016\/j.gendis.2025.102025_bib9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.gendis.2025.102025_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101020","article-title":"Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I\/II clinical study by intradermal route in healthy subjects in India","volume":"38","author":"Momin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.gendis.2025.102025_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-021-00723-0","article-title":"Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2","volume":"11","author":"Cao","year":"2021","journal-title":"Cell Biosci"},{"key":"10.1016\/j.gendis.2025.102025_bib12","article-title":"Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.gendis.2025.102025_bib127","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib128","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib129","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa2116747","article-title":"Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2. S priming","volume":"386","author":"Sablerolles","year":"2022","journal-title":"N Engl J Med"},{"issue":"620","key":"10.1016\/j.gendis.2025.102025_bib130","doi-asserted-by":"crossref","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","article-title":"AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein\u2013specific TH1 response with a diverse TCR repertoire","volume":"13","author":"Swanson","year":"2021","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.gendis.2025.102025_bib131","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.gendis.2025.102025_bib132","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.gendis.2025.102025_bib133","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.gendis.2025.102025_bib134","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.gendis.2025.102025_bib14","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.gendis.2025.102025_bib15","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.chom.2009.11.006","article-title":"Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit","volume":"6","author":"Bremner","year":"2009","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib17","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1128\/JVI.02257-14","article-title":"The amphipathic helix of adenovirus capsid protein VI contributes to penton release and postentry sorting","volume":"89","author":"Martinez","year":"2015","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/10799900050023906","article-title":"Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines","volume":"20","author":"Kim","year":"2000","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1743-422X-8-7","article-title":"GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease","volume":"8","author":"Zhang","year":"2011","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib137","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2025.102025_bib138","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0711976105","article-title":"The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine","volume":"105","author":"Trumpfheller","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2025.102025_bib139","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1081\/LPR-120004792","article-title":"Liposome (Lipodine\u2122)-mediated DNA vaccination by the oral route","volume":"12","author":"Perrie","year":"2002","journal-title":"J Liposome Res"},{"key":"10.1016\/j.gendis.2025.102025_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.08.004","article-title":"DNA-loaded cationic liposomes efficiently function as a vaccine against malarial proteins","volume":"7","author":"Fotoran","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1073\/pnas.97.2.811","article-title":"Cationic microparticles: a potent delivery system for DNA vaccines","volume":"97","author":"Singh","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib141","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expet Rev Vaccines"},{"issue":"8","key":"10.1016\/j.gendis.2025.102025_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29040","article-title":"Co-delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1-dominant humoral and cellular immunity against SARS-CoV-2","volume":"95","author":"Liao","year":"2023","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib143","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2460\/javma.1991.199.10.1433","article-title":"Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection","volume":"199","author":"Clark","year":"1991","journal-title":"J Am Vet Med Assoc"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib144","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/JVI.76.9.4536-4546.2002","article-title":"Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines","volume":"76","author":"Arrington","year":"2002","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib145","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.4049\/jimmunol.175.6.3882","article-title":"Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin","volume":"175","author":"Applequist","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib146","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18750-3","article-title":"STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines","volume":"12","author":"Padron-Regalado","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2025.102025_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861710","article-title":"STING is required in conventional dendritic cells for DNA vaccine induction of type IT helper cell-dependent antibody responses","volume":"13","author":"Ulrich-Lewis","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.gendis.2025.102025_bib148","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"6284","key":"10.1016\/j.gendis.2025.102025_bib18","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gendis.2025.102025_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666983","article-title":"How to train your dragon: harnessing gamma delta T cells antiviral functions and trained immunity in a pandemic era","volume":"12","author":"Caron","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.gendis.2025.102025_bib23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2019.02.063","article-title":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","volume":"37","author":"Zhan","year":"2019","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26. COV2. S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41467-024-44830-1","article-title":"Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models","volume":"15","author":"Guimaraes","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/vaccines9040307","article-title":"Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates","volume":"9","author":"Seo","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib27","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"L\u00f3pez-Camacho","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.gendis.2025.102025_bib28","first-page":"389","article-title":"Construction of first-generation adenoviral vectors","volume":"69","author":"Ng","year":"2002","journal-title":"Methods Mol Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nm0696-714","article-title":"Second\u2013generation adenovirus vectors","volume":"2","author":"Wang","year":"1996","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib30","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther"},{"issue":"15","key":"10.1016\/j.gendis.2025.102025_bib31","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26\u2013and modified vaccinia ankara\u2013vectored ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-024-00833-z","article-title":"Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1\/1b trials","volume":"9","author":"Happe","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"10275","key":"10.1016\/j.gendis.2025.102025_bib33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib149","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1462-5822.2007.00884.x","article-title":"The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice","volume":"9","author":"Palma","year":"2007","journal-title":"Cell Microbiol"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib39","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.ymthe.2022.01.013","article-title":"Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences","volume":"30","author":"Sankaradoss","year":"2022","journal-title":"Mol Ther"},{"issue":"26","key":"10.1016\/j.gendis.2025.102025_bib150","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","article-title":"Vaccine effectiveness of JYNNEOS against mpox disease in the United States","volume":"388","author":"Deputy","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib151","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/vaccines12020210","article-title":"Long-term clinical safety of the Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: a prospective, multi-country, observational study","volume":"12","author":"Puri","year":"2024","journal-title":"Vaccines"},{"issue":"9871","key":"10.1016\/j.gendis.2025.102025_bib61","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib152","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167664","article-title":"ALVAC-HIV and AIDSVAX B\/E vaccination induce improved immune responses compared with AIDSVAX B\/E vaccination alone","volume":"8","author":"Costanzo","year":"2023","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210252","article-title":"Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge","volume":"14","author":"Hansen","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib154","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib155","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910938","article-title":"Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fc\u03b3 receptor-activating antibodies","volume":"12","author":"Demminger","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib156","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.vaccine.2011.01.039","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok\u00ae trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50\u201364 years of age","volume":"29","author":"Baxter","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib157","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1093\/nar\/gkae142","article-title":"An engineered baculoviral protein and DNA co-delivery system for CRISPR-based mammalian genome editing","volume":"52","author":"Capin","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib158","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.gendis.2025.102025_bib159","series-title":"Gene Gun Technologies: Applications for Gene Therapy and Genetic Immunization. Gene Therapy","first-page":"281","author":"Barry","year":"2000"},{"issue":"14","key":"10.1016\/j.gendis.2025.102025_bib160","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles for drug and vaccine delivery","volume":"64","author":"Kim","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"29","key":"10.1016\/j.gendis.2025.102025_bib161","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.vaccine.2019.05.054","article-title":"Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses","volume":"37","author":"Jiang","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib162","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1022983907223","article-title":"Sonoporation: mechanical DNA delivery by ultrasonic cavitation","volume":"27","author":"Miller","year":"2002","journal-title":"Somat Cell Mol Genet"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib163","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expet Rev Vaccines"},{"issue":"7","key":"10.1016\/j.gendis.2025.102025_bib164","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"10.1016\/j.gendis.2025.102025_bib165","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1158\/0008-5472.CAN-11-1766","article-title":"Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells","volume":"71","author":"Daftarian","year":"2011","journal-title":"Cancer Res"},{"issue":"4\u20135","key":"10.1016\/j.gendis.2025.102025_bib166","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.addr.2007.10.008","article-title":"Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers","volume":"60","author":"Torchilin","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"40","key":"10.1016\/j.gendis.2025.102025_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202204462","article-title":"Lipid-polymer hybrid \u201cParticle-in-Particle\u201d nanostructure gene delivery platform explored for lyophilizable DNA and mRNA COVID-19 vaccines","volume":"32","author":"Li","year":"2022","journal-title":"Adv Funct Mater"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib167","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1021\/nl404560v","article-title":"A peptide-based nanofibrous hydrogel as a promising DNA nanovector for optimizing the efficacy of HIV vaccine","volume":"14","author":"Tian","year":"2014","journal-title":"Nano Lett"},{"issue":"24","key":"10.1016\/j.gendis.2025.102025_bib168","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1002\/anie.202010282","article-title":"Biopolymer-based carriers for DNA vaccine design","volume":"60","author":"Franck","year":"2021","journal-title":"Angew Chem Int Ed"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib169","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"El Andaloussi","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib34","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities","volume":"9","author":"Ghattas","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib170","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2448405","article-title":"Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: a randomized, observer-blind, placebo-controlled phase 2 trial","volume":"21","author":"Jia","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"10277","key":"10.1016\/j.gendis.2025.102025_bib171","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"10300","key":"10.1016\/j.gendis.2025.102025_bib172","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.gendis.2025.102025_bib173","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26. COV2. S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.gendis.2025.102025_bib174","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1473-3099(24)00419-5","article-title":"Effectiveness of rVSV-ZEBOV vaccination during the 2018\u201320 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study","volume":"24","author":"Meakin","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"issue":"10008","key":"10.1016\/j.gendis.2025.102025_bib36","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/vaccines8020307","article-title":"Immunogenicity and efficacy of zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines","volume":"8","author":"L\u00f3pez-Camacho","year":"2020","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26. ZIKV. 001, an Ad26-vectored anti\u2013Zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gendis.2025.102025_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fcimb.2017.00175","article-title":"Effective protection induced by a monovalent DNA vaccine against dengue virus (DV) serotype 1 and a bivalent DNA vaccine against DV1 and DV2 in mice","volume":"7","author":"Zheng","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.gendis.2025.102025_bib41","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/jiac445","article-title":"Safety and immunogenicity of Ad26-vectored HIV vaccine with mosaic immunogens and a novel mosaic envelope protein in HIV-uninfected adults: a phase 1\/2a study","volume":"227","author":"Stieh","year":"2023","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.gendis.2025.102025_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137079","article-title":"Robust antibody and cellular responses induced by DNA-only vaccination for HIV","volume":"5","author":"De Rosa","year":"2020","journal-title":"JCI Insight"},{"issue":"10240","key":"10.1016\/j.gendis.2025.102025_bib43","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"78","key":"10.1016\/j.gendis.2025.102025_bib44","doi-asserted-by":"crossref","first-page":"eadd3899","DOI":"10.1126\/sciimmunol.add3899","article-title":"Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination","volume":"7","author":"Maringer","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2333104","article-title":"Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan","volume":"20","author":"Jaber","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12916-023-02942-3","article-title":"Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA. 2 infection","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.102025_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib49","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/IAI.73.5.2974-2985.2005","article-title":"Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine","volume":"73","author":"Scorza","year":"2005","journal-title":"Infect Immun"},{"issue":"14","key":"10.1016\/j.gendis.2025.102025_bib51","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.vaccine.2011.06.029","article-title":"Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice","volume":"30","author":"Yuan","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-023-00623-z","article-title":"Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M. tb in conventional and humanized mice","volume":"8","author":"Afkhami","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/CVI.00690-12","article-title":"Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques","volume":"20","author":"White","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196815","article-title":"A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis","volume":"13","author":"Leung-Theung-Long","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.gendis.2025.102025_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135009","article-title":"AdHu5Ag85A respiratory mucosal boost immunization enhances protection against pulmonary tuberculosis in BCG-primed non-human primates","volume":"10","author":"Jeyanathan","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gendis.2025.102025_bib57","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/mi.2015.29","article-title":"Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection","volume":"8","author":"Jeyanathan","year":"2015","journal-title":"Mucosal Immunol"},{"issue":"205","key":"10.1016\/j.gendis.2025.102025_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus\u2013based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106205","article-title":"Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route","volume":"89","author":"Audran","year":"2024","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib60","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.1302523","article-title":"A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis","volume":"193","author":"Beverley","year":"2014","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(23)00501-7","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","volume":"24","author":"Wajja","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","article-title":"Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients","volume":"16","author":"Zhang","year":"2024","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-021-00872-4","article-title":"Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation","volume":"13","author":"Li","year":"2021","journal-title":"Genome Med"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib67","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/neuonc\/noaa170","article-title":"Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma","volume":"22","author":"Woroniecka","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.gendis.2025.102025_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039226","article-title":"Combination TIGIT\/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"39","key":"10.1016\/j.gendis.2025.102025_bib71","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1016\/j.vaccine.2010.12.063","article-title":"A phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients","volume":"29","author":"Staff","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib72","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2395680","article-title":"Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer","volume":"20","author":"Tonelli","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"10.1016\/j.gendis.2025.102025_bib73","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/vaccines13030237","article-title":"Recent advances in the development and efficacy of anti-cancer vaccines\u2014A narrative review","volume":"13","author":"Kie\u0142bowski","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib75","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12967-023-04519-3","article-title":"Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk","volume":"21","author":"Qin","year":"2023","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CJI.0000000000000348","article-title":"Re-examination of MAGE-A3 as a T-cell therapeutic target","volume":"44","author":"Martin","year":"2021","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib77","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"Davis","year":"2001","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib78","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.3390\/vaccines10122062","article-title":"Efficacy of DNA vaccines in protecting rainbow trout against VHS and IHN under intensive farming conditions","volume":"10","author":"Marsella","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/vco.12057","article-title":"A retrospective analysis of the efficacy of oncept vaccine for the adjunct treatment of canine oral malignant melanoma","volume":"11","author":"Ottnod","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2009.03.004","article-title":"Foot-and-Mouth disease virus neutralizing antibodies production induced by pcDNA3 and Sindbis virus based plasmid encoding FMDV P1-2A3C3D in swine","volume":"83","author":"Dory","year":"2009","journal-title":"Antivir Res"},{"issue":"48","key":"10.1016\/j.gendis.2025.102025_bib81","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2018.10.031","article-title":"Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine","volume":"36","author":"Barrera","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib82","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/CVI.00180-10","article-title":"Assessment of route of administration and dose escalation for an adenovirus-based influenza A virus (H5N1) vaccine in chickens","volume":"17","author":"Steitz","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.gendis.2025.102025_bib83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1746-6148-8-132","article-title":"Co-administration of avian influenza virus H5 plasmid DNA with chicken IL-15 and IL-18 enhanced chickens immune responses","volume":"8","author":"Lim","year":"2012","journal-title":"BMC Vet Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib84","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41587-023-01682-2","article-title":"Rapid-response manufacturing of adenovirus-vectored vaccines","volume":"41","author":"Joe","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol Bioeng"},{"issue":"20","key":"10.1016\/j.gendis.2025.102025_bib86","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.vaccine.2015.03.036","article-title":"Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials","volume":"33","author":"Jin","year":"2015","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.gendis.2025.102025_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J Mol Biol"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib88","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.165.5.2850","article-title":"Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice","volume":"165","author":"Dupuis","year":"2000","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.gendis.2025.102025_bib89","first-page":"5845","article-title":"Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma","volume":"62","author":"Timmerman","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib90","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4161\/hv.2836","article-title":"Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines","volume":"2","author":"Leamy","year":"2006","journal-title":"Hum Vaccin"},{"issue":"4\u20136","key":"10.1016\/j.gendis.2025.102025_bib91","first-page":"258","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2001","journal-title":"Intervirology"},{"issue":"11","key":"10.1016\/j.gendis.2025.102025_bib92","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.70053","article-title":"New insights for the development of efficient DNA vaccines","volume":"17","author":"Berger","year":"2024","journal-title":"Microb Biotechnol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/hum.1997.8.3-293","article-title":"Do DNA vaccines induce autoimmune disease?","volume":"8","author":"Mor","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib95","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4049\/jimmunol.173.1.550","article-title":"The hybrid cytomegalovirus enhancer\/chicken \u03b2-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines","volume":"173","author":"Garg","year":"2004","journal-title":"J Immunol"},{"issue":"30","key":"10.1016\/j.gendis.2025.102025_bib96","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.gendis.2025.102025_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-016-0599-y","article-title":"Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against Avian influenza virus H5N1 in mice and chickens","volume":"13","author":"Stachyra","year":"2016","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"6510","key":"10.1016\/j.gendis.2025.102025_bib99","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.gendis.2025.102025_bib100","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/mt.2013.85","article-title":"Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses","volume":"21","author":"Dietz","year":"2013","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13578-024-01338-x","article-title":"Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods","volume":"14","author":"Peng","year":"2024","journal-title":"Cell Biosci"},{"issue":"45","key":"10.1016\/j.gendis.2025.102025_bib102","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110817118","article-title":"An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination","volume":"118","author":"Xia","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib103","doi-asserted-by":"crossref","first-page":"9702","DOI":"10.1021\/acsnano.8b04146","article-title":"Enhanced cancer vaccination by in situ nanomicelle-generating dissolving microneedles","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03085-22","article-title":"Dual-targeting polymer nanoparticles efficiently deliver DNA vaccine and induce robust prophylactic immunity against spring viremia of carp virus infection","volume":"10","author":"Zhang","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib107","doi-asserted-by":"crossref","first-page":"102061","DOI":"10.1016\/j.omtn.2024.102261","article-title":"Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer","volume":"35","author":"Yang","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib108","doi-asserted-by":"crossref","first-page":"102035","DOI":"10.1016\/j.xcrm.2025.102035","article-title":"Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity","volume":"6","author":"Tursi","year":"2025","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1016\/j.gendis.2025.102025_bib109","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"748","key":"10.1016\/j.gendis.2025.102025_bib110","doi-asserted-by":"crossref","first-page":"eadn0223","DOI":"10.1126\/scitranslmed.adn0223","article-title":"Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice","volume":"16","author":"Cottrell","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.gendis.2025.102025_bib111","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13578-016-0080-z","article-title":"Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease","volume":"6","author":"Peng","year":"2016","journal-title":"Cell Biosci"},{"issue":"10","key":"10.1016\/j.gendis.2025.102025_bib112","article-title":"Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors","volume":"2","author":"Cao","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib113","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/hum.2019.074","article-title":"In vitro validation of a CRISPR-mediated CFTR correction strategy for preclinical translation in pigs","volume":"30","author":"Zhou","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/genes10010039","article-title":"TALEN-mediated gene targeting for cystic fibrosis-gene therapy","volume":"10","author":"Xia","year":"2019","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib115","doi-asserted-by":"crossref","first-page":"2000205","DOI":"10.1183\/13993003.00205-2020","article-title":"A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations","volume":"56","author":"Cao","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.gendis.2025.102025_bib116","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.omtn.2018.10.015","article-title":"Overcoming the undesirable CRISPR-Cas9 expression in gene correction","volume":"13","author":"Xia","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"10.1016\/j.gendis.2025.102025_bib117","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.cr.7290275","article-title":"Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference","volume":"15","author":"Cao","year":"2005","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.102025_bib118","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1525-0016(03)00059-5","article-title":"Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter","volume":"7","author":"Toietta","year":"2003","journal-title":"Mol Ther"},{"issue":"630","key":"10.1016\/j.gendis.2025.102025_bib119","doi-asserted-by":"crossref","first-page":"eabm3302","DOI":"10.1126\/scitranslmed.abm3302","article-title":"Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains","volume":"14","author":"Ying","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.gendis.2025.102025_bib120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/vaccines9040324","article-title":"BNT162b2 vaccine encoding the SARS-CoV-2 P2 S protects transgenic hACE2 mice against COVID-19","volume":"9","author":"Ji","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"23","key":"10.1016\/j.gendis.2025.102025_bib121","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1158\/1078-0432.CCR-18-1013","article-title":"A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy","volume":"24","author":"Duperret","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.gendis.2025.102025_bib122","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2025.102025_bib123","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00262-024-03770-x","article-title":"TRP-2\/gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors","volume":"73","author":"Pearson","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.gendis.2025.102025_bib124","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.gendis.2025.102025_bib125","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/QAD.0000000000003804","article-title":"The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy","volume":"38","author":"Jacobson","year":"2024","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.gendis.2025.102025_bib126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-023-00795-8","article-title":"Development and use of machine learning algorithms in vaccine target selection","volume":"9","author":"Bravi","year":"2024","journal-title":"NPJ Vaccines"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225005148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225005148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:46:11Z","timestamp":1790012771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225005148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2352304225005148"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.102025","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-based vaccines: Advances, applications, and future prospects","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.102025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102025"}}